Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q2 2023 · 10-Q
Revenue$399.13K$399.13K−15.0% vs Q2 2022 Net Income-$1.86M-$1.86MN/M vs Q2 2022 EPS Diluted-$0.11-$0.11N/M vs Q2 2022 Gross Profit$202,814+47.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$483,316N/M Free Cash Flowderived-$492,666N/M Margins · derivedGross margin50.8%+21.4 pt vs Q2 2022
Operating margin-269.1%−5.0 pt vs Q2 2022
Net margin-467.1%−49.2 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 15, 2023 · 46 d after period end